Effect of Emblica officinalis (Amla) Extract Versus Exercise on Lipid Levels in Participants With Abnormal Lipid Levels: An Open-Label Clinical Study

IF 1.5 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2025-01-01 DOI:10.1016/j.curtheres.2025.100800

Kiran Jagalurappa MD , Giriraja Kanakapura Vrushabaiah MD , Suman Govindaraj BDS

{"title":"Effect of Emblica officinalis (Amla) Extract Versus Exercise on Lipid Levels in Participants With Abnormal Lipid Levels: An Open-Label Clinical Study","authors":"Kiran Jagalurappa MD , Giriraja Kanakapura Vrushabaiah MD , Suman Govindaraj BDS","doi":"10.1016/j.curtheres.2025.100800","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Dyslipidemia, marked by abnormal lipid levels, significantly increases the risk of cardiovascular diseases. Effective management of these lipid abnormalities is essential for reducing cardiovascular risk. <em>Emblica officinalis</em>, known as amla in Ayurveda, is traditionally considered the best fruit due to its numerous health benefits.</div></div><div><h3>Objective</h3><div>To evaluate the efficacy and tolerability of amla extract on participants with abnormal lipid levels and compare with the effect of physical activity in reducing atherogenic factors.</div></div><div><h3>Methods</h3><div>Forty-five inactive participants having abnormal lipid levels were selected and instructed to initiate lifestyle changes, including a healthy diet and aerobic exercise for 14 days. Thirty-nine participants who met the study criteria even after exercise were allocated a 500 mg capsule of amla extract (Tri-Low®) twice daily for 90 days. The effect of amla extract on lipid parameters, atherogenic index of plasma (AIP), apolipoprotein (Apo) B/Apo A ratio, high-sensitivity C-reactive protein, coenzyme Q10, and hydroxy methylglutaryl coenzyme A reductase levels was studied and compared with the effect of physical activity or exercise on these parameters. Laboratory parameters, global tolerability, and treatment-emergent adverse events were evaluated for the assessment of safety profile of amla extract.</div></div><div><h3>Results</h3><div>Amla extract over a period of 90 days significantly reduced triglyceride (<em>P</em> = 0.007), total cholesterol (<em>P</em> < 0.001), LDL (<em>P</em> = 0.006), VLDL (<em>P</em> = 0.014), and AIP (<em>P</em> < 0.001) but reported no significant effect on HDL (<em>P</em> = 0.967) and fasting blood sugar (<em>P</em> = 1.00). Varying the intensity of exercise from low to moderate and high had no significant effect on triglyceride (<em>P</em> = 0.516), total cholesterol (<em>P</em> = 0.676), LDL (<em>P</em> = 0.511), VLDL (<em>P</em> = 0.454), or AIP (<em>P</em> = 0.472). However, LDL exhibited a significant reduction with amla extract, combined with exercise (<em>P</em> < 0.001). Apolipoprotein B/Apo A1 ratio exhibited a trend toward significance (<em>P</em> = 0.061). Weight and reductions were statistically significant with amla extract and exercise, after 45 days (<em>P</em> < 0.001) and 90 days (<em>P</em> = 0.002). Hydroxy methylglutaryl coenzyme A, Apo B, and coenzyme Q10 exhibited no significant changes. Overall, it was evident that the significant changes in lipid parameters are attributable to amla extract rather than physical activity alone. All other factors are not affected by exercise intensity, and the significant changes observed are purely due to the effect of amla extract.</div></div><div><h3>Conclusions</h3><div>Exercise alone is often insufficient for optimal cardiovascular health. The supplementation of amla extract (Tri-Low®) from this study reported significant potential in improving lipid profiles and other atherogenic factors, thereby providing a comprehensive strategy for cardiovascular health management.</div></div><div><h3>Clinical Trial Registration</h3><div>Clinical Trial Registry - India (CTRI/2017/02/007829).</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"103 ","pages":"Article 100800"},"PeriodicalIF":1.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X25000256","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Dyslipidemia, marked by abnormal lipid levels, significantly increases the risk of cardiovascular diseases. Effective management of these lipid abnormalities is essential for reducing cardiovascular risk. Emblica officinalis, known as amla in Ayurveda, is traditionally considered the best fruit due to its numerous health benefits.

Objective

To evaluate the efficacy and tolerability of amla extract on participants with abnormal lipid levels and compare with the effect of physical activity in reducing atherogenic factors.

Methods

Forty-five inactive participants having abnormal lipid levels were selected and instructed to initiate lifestyle changes, including a healthy diet and aerobic exercise for 14 days. Thirty-nine participants who met the study criteria even after exercise were allocated a 500 mg capsule of amla extract (Tri-Low®) twice daily for 90 days. The effect of amla extract on lipid parameters, atherogenic index of plasma (AIP), apolipoprotein (Apo) B/Apo A ratio, high-sensitivity C-reactive protein, coenzyme Q10, and hydroxy methylglutaryl coenzyme A reductase levels was studied and compared with the effect of physical activity or exercise on these parameters. Laboratory parameters, global tolerability, and treatment-emergent adverse events were evaluated for the assessment of safety profile of amla extract.

Results

Amla extract over a period of 90 days significantly reduced triglyceride (P = 0.007), total cholesterol (P < 0.001), LDL (P = 0.006), VLDL (P = 0.014), and AIP (P < 0.001) but reported no significant effect on HDL (P = 0.967) and fasting blood sugar (P = 1.00). Varying the intensity of exercise from low to moderate and high had no significant effect on triglyceride (P = 0.516), total cholesterol (P = 0.676), LDL (P = 0.511), VLDL (P = 0.454), or AIP (P = 0.472). However, LDL exhibited a significant reduction with amla extract, combined with exercise (P < 0.001). Apolipoprotein B/Apo A1 ratio exhibited a trend toward significance (P = 0.061). Weight and reductions were statistically significant with amla extract and exercise, after 45 days (P < 0.001) and 90 days (P = 0.002). Hydroxy methylglutaryl coenzyme A, Apo B, and coenzyme Q10 exhibited no significant changes. Overall, it was evident that the significant changes in lipid parameters are attributable to amla extract rather than physical activity alone. All other factors are not affected by exercise intensity, and the significant changes observed are purely due to the effect of amla extract.

Conclusions

Exercise alone is often insufficient for optimal cardiovascular health. The supplementation of amla extract (Tri-Low®) from this study reported significant potential in improving lipid profiles and other atherogenic factors, thereby providing a comprehensive strategy for cardiovascular health management.

Clinical Trial Registration

Clinical Trial Registry - India (CTRI/2017/02/007829).

查看原文本刊更多论文

officinalis （Amla）提取物与运动对血脂水平异常参与者血脂水平的影响：一项开放标签临床研究

背景：以脂质水平异常为标志的血脂异常会显著增加心血管疾病的风险。有效管理这些脂质异常对于降低心血管风险至关重要。在阿育吠陀语中，Emblica officinalis被称为amla，传统上被认为是最好的水果，因为它对健康有很多好处。目的评价枸杞提取物对血脂异常患者的疗效和耐受性，并与体育锻炼对降低动脉粥样硬化因子的影响进行比较。方法选择45名血脂水平异常的非运动参与者，指导他们开始改变生活方式，包括健康饮食和有氧运动14天。39名即使在运动后也符合研究标准的参与者每天两次服用500毫克的amla提取物胶囊（Tri-Low®），持续90天。研究了木树提取物对血脂参数、血浆动脉粥样硬化指数（AIP）、载脂蛋白（Apo） B/Apo A比值、高敏c反应蛋白、辅酶Q10和羟甲基戊二酰辅酶A还原酶水平的影响，并与体育锻炼对这些参数的影响进行了比较。实验室参数，整体耐受性和治疗中出现的不良事件进行评估，以评估amla提取物的安全性。结果samla提取物在90天内显著降低甘油三酯（P = 0.007）、总胆固醇(P <；0.001),低密度脂蛋白(P = 0.006),VLDL (P = 0.014),和航(P & lt;0.001)，但对HDL （P = 0.967）和空腹血糖（P = 1.00）无显著影响。不同强度的运动从低到中等和高甘油三酯无显著影响(P = 0.516)、总胆固醇(P = 0.676),低密度脂蛋白(P = 0.511),VLDL (P = 0.454),或AIP (P = 0.472)。然而，与运动相结合的amla提取物显著降低了LDL (P <；0.001)。载脂蛋白B/载脂蛋白A1比值有显著性趋势（P = 0.061）。45天后，服用苦参提取物和运动的患者体重和减轻程度均有统计学意义(P <；0.001)和90天（P = 0.002）。羟甲基戊二酰辅酶A、载脂蛋白B和辅酶Q10无显著变化。总的来说，很明显，脂质参数的显著变化可归因于amla提取物，而不仅仅是身体活动。所有其他因素不受运动强度的影响，观察到的显著变化纯粹是由于amla提取物的作用。结论单纯运动不足以达到最佳的心血管健康状态。本研究报告了补充amla提取物（Tri-Low®）在改善脂质谱和其他动脉粥样硬化因素方面的显著潜力，从而为心血管健康管理提供了一种全面的策略。临床试验注册印度临床试验注册中心（CTRI/2017/02/007829）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.